New Delhi, Sept 8 (UNI) Mankind Pharma, a leading pharmaceutical company, announced today that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial of MKP11093, a novel orally administered Janus kinase-1 (JAK-1) inhibitor.
The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis, and alopecia, the company said in a statement here.
"Developed at the Mankind Research Centre, MKP11093 has demonstrated strong results in preclinical studies, showing a promising safety and selectivity profile. The molecule targets JAK-1, a key enzyme in the JAK family (JAK1, JAK2, JAK3, TYK2). By inhibiting these enzymes, MKP11093 disrupts the JAK/STAT signaling pathway and reduces the activity of several pro-inflammatory cytokines. This makes it a unique treatment candidate with the potential to deliver improved outcomes in autoimmune diseases," the statement added.
The Phase 1 trial is expected to commence shortly and will assess the safety, tolerability, and pharmacokinetics of MKP11093 in healthy volunteers through single and multiple ascending dose studies.
Another candidate from Mankind Pharma's pipeline, MKP10241, has successfully completed Phase 1 trials and is currently in Phase 2 development for obesity and diabetes, the statement noted.
Commenting on the development, Arjun Juneja, Chief Operating Officer of Mankind Pharma, said, "The development of MKP11093 is a major milestone in our endeavour to deliver a best-in-class JAK inhibitor that maximises therapeutic potential while addressing the safety concerns associated with conventional approaches."